| Cash flow (USD) | FY 2026 ended May 31, 2026 | FY 2025 ended May 31, 2025 | FY 2024 ended May 31, 2024 | FY 2023 ended May 31, 2023 | FY 2022 ended May 31, 2022 | FY 2021 ended May 31, 2021 |
|---|---|---|---|---|---|---|
| Net income | -36.74M | -33.99M | -184.35M | -52.44M | -26.55M | -31.55M |
| Depreciation and amortization | 22.95M | 25.80M | 27.71M | 30.87M | 29.35M | 25.92M |
| Stock-based compensation | 13.96M | 9.77M | 10.53M | 11.16M | 10.69M | 8.63M |
| Cash from operations | 3.09M | -10.13M | -28.16M | 78.0K | -7.19M | 24.09M |
| Capital expenditure | -2.58M | -4.46M | -2.52M | -3.81M | -4.30M | -5.19M |
| Free cash flow | 508.0K | -14.59M | -30.68M | -3.73M | -11.49M | 18.91M |
| Cash from investing | -5.95M | -10.18M | 123.72M | -9.75M | -19.31M | -13.71M |
| Share buybacks | 0 | -1.67M | 0 | 0 | ||
| Net debt issued | 0 | 0 | -50.00M | -45.00M | 0 | -20.00M |
| Cash from financing | 564.0K | -255.0K | -64.25M | 25.42M | 7.68M | -16.99M |
| Net change in cash | -2.03M | -20.16M | 31.44M | 15.79M | -19.34M | -6.27M |
From Angiodynamics Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.